locals Tuğçe Koç describes the company’s initial aspirations in targeting the higher value-added therapeutic area of oncology and the type of market opportunities that are present domestically and internationally. With over 25 years of experience, Onko Koçsel has established a strong foothold in the Turkish pharmaceutical industry—first with the introduction of…
locals The co-founder of Ekin Kimya discusses the need for greater regulation and monitoring of raw materials used in Turkish pharmaceutical manufacturing, his company’s key role as an educator and advisor to the industry with regards to international regulatory standards, and unique role as a supplier that provides robust support services,…
locals The chairman and CEO of Santa Farma discusses how the Turkish pharmaceutical landscape has evolved in response to the government’s healthcare transformation programs. He also enumerates various strategic initiatives the company is pursuing to bolster its competitive positioning the market such as constructing new state-of-the-art production and R&D facilities, penetrating…
locals The CEO of Centurion shares his ambitious vision for the company’s expansion into plasma products, biotech, orphan drugs, and generic injectables over the coming years, while simultaneously developing sales in more than twenty countries across the EU, CIS, GCC and MENA regions. As a company working on bringing biotech production to Turkey,…
locals Keyman’s general manager discusses his firm’s development efforts towards vaccine production, in conjunction with TUBITAK and Hacettepe University, and their geographic expansion into Africa, Latin America, and Southeast Asia. Please introduce Keymen and explain the company in the broader context of the Turkish pharmaceutical market. Keymen is a family company…
locals Imuneks is currently operating in the OTC market, but with three supergeneric products ready to market on the RX side, the firm has the potential to soon become one of Turkey’s most innovative pharmaceutical players. To begin, could you please introduce yourself and Imuneks to our readers around the world?…
R&D “When I left Janssen, I never imagined joining a Korean company,” recalls Choi Tae-Hung, sipping a freshly brewed yujacha tea in his office on a crisp autumn morning as he gazes down at the busy, sundrenched streets of Seoul below. “I thought that the global business of Korean pharmaceutical companies…
See our Cookie Privacy Policy Here